UBRS20139 / FACT-5 / Ajay Dhakal
Basic Study Information
Purpose:Location: University of Rochester
The purpose of this research is to look at the safety and effectiveness of a HER2-targeted
therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer
patients with brain metastases whose tumors were HER2-negative by standard tests but
showed abnormal HER2 activity based on the CELsignia results.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search